Pattern of semaglutide prescription in a real-world Canadian patient cohort
Open Access
- 24 June 2025
- journal article
- Published by Elsevier in Primary Care Diabetes
- Vol. 19 (5) , 512-516
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered studyInternational Journal of Obesity, 2024
- Medications and conditions associated with weight loss in patients prescribed semaglutide based on real‐world dataObesity, 2023
- Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trialNature Medicine, 2022
- Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or ObesityJAMA Network Open, 2022
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 DiabetesNew England Journal of Medicine, 2021
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or ObesityJAMA, 2021
- Once-Weekly Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine, 2021
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trialThe Lancet, 2021
- Semaglutide: First Global ApprovalDrugs, 2018
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2017